Education Course Speakers | pages.pnsociety.com

Education Course Speakers

Jérôme Devaux, PhD

Institut de Neurosciences de Montpellier

The Node of Ranvier: Latest and Breaking News

CNRS staff scientist since 2005, I did my PhD at Aix-Marseille University followed by a post-doctoral fellowship at the University of Pennsylvania. I am interested in understanding the pathogenic mechanisms leading to conduction loss in human demyelinating neuropathies and in understanding the function of axonal voltage-gated potassium channels (Kv). We recently demonstrated that cell adhesion molecules of the nodes of Ranvier, are the targets of autoantibodies in patients suffering from chronic inflammatory demyelinating polyneuropathy. Using animal models, we showed that these antibodies are pathogenic and affect the structure of the node of Ranvier. These proteins now serve as biomarkers for this pathology and help therapeutic choice. In addition, we have demonstrated that Kv channels (Kv7.2/3 and Kv3.1) are localized at nodes, and that human mutation affect their trafficking or function.

Eva Feldman, MD

University of Michigan Department of Neurology

Mechanisms in Diabetic Neuropathy: An Update

Eva L. Feldman, M.D., Ph.D., is the Russell N. DeJong Professor of Neurology at the University of Michigan (U-M).  A neurologist and neuroscientist, she earned her medical and doctoral degrees at U-M and completed neurology training at Johns Hopkins Hospital. With 30 years of continuous NIH funding, Dr. Feldman has pioneered studies on neurological disorders in metabolic diseases. Her work identified dyslipidemia during obesity and diabetes as a driver of brain and nerve damage in children and adults, influencing new patient care guidelines. She currently leads three multi-institutional NIH grants aimed at understanding how lipids cause nervous system injury, with a focus on neuropathy. At U-M, she directs a research program of 25 scientists, and has trained over 100 fellows. Dr. Feldman served as president of the Peripheral Nerve Society (2007-2009), the American Neurological Association (2011-2013), and is a member of the National Academy of Medicine.

Alexander Rossor, PhD, FRCP

Queen Square Institute of Neurology, University College London

Peripheral Neuropathy in Complex Genetic Diseases: Approach to Diagnosis

Alex Rossor is an honorary consultant neurologist and previous Wellcome Trust Post-Doctoral Clinical Fellow at the UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery, London, United Kingdom. His research and clinical interest is Charcot-Marie-Tooth disease and related disorders in which peripheral neuropathy is seen as part of a complex multi-system disease.

Peripheral neuropathy is a common finding in patients with complex inherited neurological disease and may be subclinical or a major component of the phenotype. In this talk I will provide an approach to diagnosis for this complex group of patients by addressing key questions including the predominant neurological syndrome, the type of neuropathy, and the other neurological and non-neurological features of the syndrome. The presented approach will give priority to the diagnosis of treatable diseases as well as presenting a format for investigating this group of patients

James Sejvar, MD

Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zooonotic Infectious Diseases, Centers for Disease Control and Prevention

Infections and the Peripheral Nervous System

James J. Sejvar, M.D., Neuroepidemiologist, Division of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention; Assistant Professor of Medicine, Department of Neurology, Emory University School of Medicine; Consultant Neuroepidemiologist, Duke-NUS Graduate Medical School Singapore Dr. Sejvar graduated from Case Western Reserve University, Cleveland, Ohio in 1991 (B.A.). In 1996, he obtained his medical degree from Dartmouth Medical School in Hanover, New Hampshire. He received his training in neurology at the Mayo Clinic in Rochester, Minnesota, completing residency in 2000. He then did a fellowship in applied field epidemiology through CDC’s Epidemic Intelligence Service. Following completion of the program in 2002, he remained at CDC, where he serves as a neuroepidemiologist at CDC’s Divisions of High-Consequence Pathogens and Pathology. He is board-certified in neurology, and serves on the faculty of the Department of Neurology at Emory University in Atlanta, Georgia. His current research focus centers on the epidemiology, pathogenesis, clinical features, and outcomes of infections of the nervous system. He has conducted numerous studies focusing on viral encephalitis, post-infectious nervous system disorders, prion diseases, and infectious etiologies of acute flaccid paralysis. He currently focuses on the establishment of surveillance for etiologies of viral encephalitis and infectious acute flaccid paralysis; and developing intervention strategies for prevention and control of neurologic infections. His research also focuses on neurologic adverse events following immunizations.

Mike Shy, MD

Carver College of Medicine, University of Iowa

Established and Emerging Outcome Measures for Hereditary Neuropathy

Dr. Shy is the Principal Investigator of the Inherited Neuropathy Consortium (INC) and the current Chair of the CMTR subgroup of the PNS. He has spent more than 25 years evaluating patients and developing both COA and biomarkers for patients with inherited neuropathies.

Clinical trial readiness is increasingly important for inherited neuropathies as rational therapeutic approaches are emerging for many genetic forms of these disorders. Effective clinical outcome measures (COA) and disease markers are necessary to carefully measure disease progression in these diseases as well as to detect target engagement. Ideal COA and biomarkers reproducible, detect significant change in a reasonable time period to enable clinical trials and demonstrate biological and clinical effects of therapies. Multiple COA utilized in inherited neuropathies will be discussed including function including functional and patient reported instruments for individuals of all ages. Biomarkers from blood, skin and imaging will be reviewed.